EA202191473A1 - Гетероциклические соединения для лечения эпилепсии - Google Patents
Гетероциклические соединения для лечения эпилепсииInfo
- Publication number
- EA202191473A1 EA202191473A1 EA202191473A EA202191473A EA202191473A1 EA 202191473 A1 EA202191473 A1 EA 202191473A1 EA 202191473 A EA202191473 A EA 202191473A EA 202191473 A EA202191473 A EA 202191473A EA 202191473 A1 EA202191473 A1 EA 202191473A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- seizure
- treatment
- epilepsy
- heterocyclic compounds
- diagnosis
- Prior art date
Links
- 206010015037 epilepsy Diseases 0.000 title abstract 2
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract 2
- 206010010904 Convulsion Diseases 0.000 abstract 6
- 208000002091 Febrile Seizures Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000028329 epileptic seizure Diseases 0.000 abstract 1
- 206010016284 febrile convulsion Diseases 0.000 abstract 1
- 230000036457 multidrug resistance Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000005809 status epilepticus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Настоящее изобретение представляет новое гетероциклическое соединение, представленное формулой [I], и его сольгде символы имеют значения, указанные в описании, которое является полезным для лечения, профилактики и/или диагностики припадка и тому подобное при заболевании, включающем эпилептический припадок или судорожный припадок (включая припадок с множественной лекарственной резистентностью, рефрактерный припадок, острый симптоматический припадок, фебрильный приступ и эпилептический статус), а также для его медицинского применения.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018224724 | 2018-11-30 | ||
| PCT/JP2019/046879 WO2020111263A1 (en) | 2018-11-30 | 2019-11-29 | Heterocyclic compounds for the treatment of epilepsy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202191473A1 true EA202191473A1 (ru) | 2021-08-27 |
Family
ID=68887096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202191473A EA202191473A1 (ru) | 2018-11-30 | 2019-11-29 | Гетероциклические соединения для лечения эпилепсии |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20210403456A1 (ru) |
| EP (1) | EP3887358A1 (ru) |
| JP (1) | JP2022509848A (ru) |
| KR (1) | KR20210097148A (ru) |
| CN (1) | CN113166076A (ru) |
| AU (1) | AU2019390907A1 (ru) |
| BR (1) | BR112021006222A2 (ru) |
| CA (1) | CA3118071A1 (ru) |
| EA (1) | EA202191473A1 (ru) |
| IL (2) | IL311021A (ru) |
| MX (1) | MX2021006364A (ru) |
| PH (1) | PH12021551233A1 (ru) |
| SG (1) | SG11202104374WA (ru) |
| TW (1) | TW202039446A (ru) |
| WO (1) | WO2020111263A1 (ru) |
| ZA (1) | ZA202103106B (ru) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021231933A1 (en) * | 2020-05-15 | 2021-11-18 | Neucyte Pharmaceuticals | Anti-epileptic pharmaceutical compositions and use thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2414612A1 (de) * | 1974-03-26 | 1975-10-16 | Bayer Ag | 1-aryluracile, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
| US4239888A (en) * | 1974-11-04 | 1980-12-16 | Pfizer Inc. | 1-Phenyluracils |
| JP2006510597A (ja) | 2002-09-27 | 2006-03-30 | メルク エンド カムパニー インコーポレーテッド | 置換ピリミジン類 |
| CA2781685C (en) | 2009-12-11 | 2018-09-04 | Autifony Therapeutics Limited | Imidazolidinedione derivatives |
| KR20120131161A (ko) | 2010-01-25 | 2012-12-04 | 씨에이치디아이 파운데이션, 인코포레이티드 | 특정 키뉴레닌-3-모노옥시게나제 억제제, 그의 제약 조성물 및 사용 방법 |
| CA2841981A1 (en) | 2011-07-28 | 2013-01-31 | Chdi Foundation, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| WO2013175215A1 (en) * | 2012-05-22 | 2013-11-28 | Autifony Therapeutics Limited | Triazoles as kv3 inhibitors |
| KR102002446B1 (ko) * | 2017-03-16 | 2019-07-22 | 재단법인 대구경북첨단의료산업진흥재단 | TGase 2 억제제로서의 퀴놀린-5,8-디온 유도체 및 이를 포함하는 약제학적 조성물 |
| WO2018220762A1 (ja) * | 2017-05-31 | 2018-12-06 | 大塚製薬株式会社 | ピリミジン化合物 |
-
2019
- 2019-11-29 WO PCT/JP2019/046879 patent/WO2020111263A1/en active Application Filing
- 2019-11-29 SG SG11202104374WA patent/SG11202104374WA/en unknown
- 2019-11-29 EA EA202191473A patent/EA202191473A1/ru unknown
- 2019-11-29 CA CA3118071A patent/CA3118071A1/en active Pending
- 2019-11-29 MX MX2021006364A patent/MX2021006364A/es unknown
- 2019-11-29 IL IL311021A patent/IL311021A/en unknown
- 2019-11-29 CN CN201980077000.2A patent/CN113166076A/zh active Pending
- 2019-11-29 AU AU2019390907A patent/AU2019390907A1/en active Pending
- 2019-11-29 TW TW108143548A patent/TW202039446A/zh unknown
- 2019-11-29 BR BR112021006222A patent/BR112021006222A2/pt unknown
- 2019-11-29 JP JP2021530270A patent/JP2022509848A/ja active Pending
- 2019-11-29 KR KR1020217019592A patent/KR20210097148A/ko unknown
- 2019-11-29 EP EP19820895.1A patent/EP3887358A1/en active Pending
- 2019-11-29 US US17/292,528 patent/US20210403456A1/en active Pending
-
2021
- 2021-04-27 IL IL282700A patent/IL282700A/en unknown
- 2021-05-07 ZA ZA2021/03106A patent/ZA202103106B/en unknown
- 2021-05-28 PH PH12021551233A patent/PH12021551233A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN113166076A (zh) | 2021-07-23 |
| EP3887358A1 (en) | 2021-10-06 |
| TW202039446A (zh) | 2020-11-01 |
| MX2021006364A (es) | 2021-08-11 |
| ZA202103106B (en) | 2022-10-26 |
| US20210403456A1 (en) | 2021-12-30 |
| IL282700A (en) | 2021-06-30 |
| JP2022509848A (ja) | 2022-01-24 |
| AU2019390907A1 (en) | 2021-05-27 |
| IL311021A (en) | 2024-04-01 |
| PH12021551233A1 (en) | 2021-12-06 |
| BR112021006222A2 (pt) | 2021-07-06 |
| WO2020111263A1 (en) | 2020-06-04 |
| KR20210097148A (ko) | 2021-08-06 |
| CA3118071A1 (en) | 2020-06-04 |
| SG11202104374WA (en) | 2021-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201591614A1 (ru) | Соединения 1,3-оксазин-2-амина, конденсированные с перфторированным циклопропилом, в качестве ингибиторов бета-секретазы и способы их применения | |
| CU20200014A7 (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona | |
| EA201071264A1 (ru) | Аминодигидротиазиновые производные в качестве ингибиторов bace для лечения болезни альцгеймера | |
| CY1124537T1 (el) | Παραγωγο πυριδονης που εχει τετραϋδροπυρανυλ μεθυλ ομαδα | |
| EA201690952A1 (ru) | Пиразол для лечения аутоиммунных расстройств | |
| EA201791656A1 (ru) | Соединения 4-метилсульфонилзамещенной пиперидинмочевины для лечения дилатационной кардиомиопатии (dcm) | |
| EA201390877A1 (ru) | Замещенные 6,6-конденсированные азотсодержащие гетероциклические соединения и их применение | |
| EA201690204A1 (ru) | Соединения n,6-бис(арил или гетероарил)-1,3,5-триазин-2,4-диамина в качестве ингибиторов мутантов idh2 для лечения ракового заболевания | |
| EA201690019A1 (ru) | Производное аминотриазина и содержащая его фармацевтическая композиция | |
| EA200901488A1 (ru) | Замещенные имидазолопиридазины, как ингибиторы липидкиназы | |
| EA201491936A1 (ru) | Азотсодержащее гетероциклическое соединение | |
| MX2011013016A (es) | Derivados de aminopirrolidinona y usos de los mismos. | |
| EA201590653A1 (ru) | Терапевтическое средство при дислипидемии | |
| MX2016008910A (es) | Compuestos de fenil-triazolo-piridina. | |
| EA202092241A1 (ru) | Кристаллическая форма тетрагидрохлорида триэтилентетрамина и ее фармацевтическое применение | |
| EA202191476A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| EA201170828A1 (ru) | Конденсированные гетероциклические производные оксадиазола, подходящие для лечения рассеянного склероза | |
| CY1125073T1 (el) | Ενωση πυριμιδινης | |
| EA202191473A1 (ru) | Гетероциклические соединения для лечения эпилепсии | |
| EA201390333A1 (ru) | Конденсированные триазолы для лечения или профилактики умеренного когнитивного нарушения | |
| EA201692264A1 (ru) | Конденсированные производные триазола в качестве ингибиторов фосфодиэстеразы 10a | |
| EA202091588A1 (ru) | Способ получения аминопиримидина и его промежуточных продуктов | |
| EA201200322A1 (ru) | Метилпирролопиримидинкарбоксамиды | |
| EA201300092A1 (ru) | Замещенные производные оксадиазола | |
| RU2013107659A (ru) | ИНГИБИТОР КАЗЕИНКИНАЗЫ 1δ И КАЗЕИНКИНАЗЫ 1ε |